Stephens Investment Management Group LLC Has $111.30 Million Stock Holdings in Exelixis, Inc. $EXEL

Stephens Investment Management Group LLC boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 1.1% in the 4th quarter, Holdings Channel reports. The institutional investor owned 2,539,421 shares of the biotechnology company’s stock after buying an additional 28,265 shares during the period. Exelixis accounts for approximately 1.4% of Stephens Investment Management Group LLC’s holdings, making the stock its 4th biggest holding. Stephens Investment Management Group LLC’s holdings in Exelixis were worth $111,303,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Richardson Financial Services Inc. grew its holdings in shares of Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 292 shares in the last quarter. RHS Financial LLC grew its holdings in shares of Exelixis by 2.4% during the 4th quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock valued at $553,000 after acquiring an additional 293 shares in the last quarter. Cim LLC grew its holdings in shares of Exelixis by 0.9% during the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock valued at $1,462,000 after acquiring an additional 305 shares in the last quarter. Evergreen Capital Management LLC grew its holdings in shares of Exelixis by 6.4% during the 3rd quarter. Evergreen Capital Management LLC now owns 5,450 shares of the biotechnology company’s stock valued at $225,000 after acquiring an additional 329 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Exelixis by 5.1% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 7,919 shares of the biotechnology company’s stock valued at $327,000 after acquiring an additional 384 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

EXEL has been the topic of several research analyst reports. HC Wainwright boosted their price target on shares of Exelixis from $54.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Zacks Research cut shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. Wells Fargo & Company boosted their price target on shares of Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Barclays boosted their price target on shares of Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a report on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Hold” and a consensus price target of $47.35.

Exelixis Trading Down 1.9%

Shares of NASDAQ:EXEL opened at $50.13 on Friday. The stock has a market capitalization of $12.60 billion, a PE ratio of 16.65, a P/E/G ratio of 1.06 and a beta of 0.38. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $51.63. The firm has a fifty day moving average price of $44.30 and a 200 day moving average price of $43.48.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. The firm had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. Exelixis’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.55 earnings per share. On average, sell-side analysts forecast that Exelixis, Inc. will post 3.15 earnings per share for the current fiscal year.

Insider Activity

In other Exelixis news, CFO Christopher J. Senner sold 30,617 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total transaction of $1,337,044.39. Following the completion of the transaction, the chief financial officer owned 976,092 shares of the company’s stock, valued at $42,625,937.64. The trade was a 3.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Patrick J. Haley sold 67,814 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the transaction, the executive vice president directly owned 381,908 shares of the company’s stock, valued at approximately $16,620,636.16. This represents a 15.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 382,811 shares of company stock worth $17,014,813. Insiders own 2.60% of the company’s stock.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.